Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical treatment for patients with acute ischemic stroke due to medium vessel occlusion.

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

The following is a summary of “Hyponatremia is associated with malignant brain edema after mechanical thrombectomy in acute ...

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE.

Participants had a first-ever stroke and prestroke functional independence (modified Rankin Scale [mRS]: 0-2) and received EVT for MeVO in the MCA territory from 2015 to 2021. Comorbidity burden was ...

Performance feedback reduces the time to endovascular thrombectomy (EVT) in patients with ischemic stroke ... outcomes (measured using the modified Rankin Scale [mRS] score at 3 months).